Abstract | BACKGROUND: OBJECTIVE: METHODS: Fifty patients from a phase II trial of IFNbeta-1a (Placebo n = 20; Avonex 1 x 30 microg/week (IFN-30), n = 15; Avonex 1 x 60 microg/week (IFN-60), n = 15), were enrolled. Patients were assessed using the Expanded Disability Status Scale. Urine samples were collected on each visit, 3 months apart, for a period of 24 months. Nitric oxide metabolites, nitrite/ nitrate (NOx), were measured by colorimetric assay and neopterin and creatinine (Cr) were assayed using a high-performance liquid chromatography technique. NOx/ creatinine ratio (NOxCR) and urinary neopterin/ creatinine ratio (UNCR) quotients were calculated. RESULTS: There was no significant difference between pre-dose, baseline levels of UNCR or NOxCR between the study groups. On the intention-to-treat analysis, there was a significant difference in UNCR levels between the placebo compared with IFN-30 (p = 0.03) or IFN-60 (p = 0.002) groups. The IFN-30 and IFN-60 groups did not differ. Within IFNbeta-1a-treated patients with primary progressive multiple sclerosis, median UNCR values were significantly higher in clinically stable (no Expanded Disability Status Scale change) compared with progressive patients (p = 0.002). IFNbeta-1a treatment did not significantly influence NOx excretion in patients with primary progressive multiple sclerosis. CONCLUSIONS:
|
Authors | K Rejdak, S M Leary, A Petzold, A J Thompson, D H Miller, G Giovannoni |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 16
Issue 9
Pg. 1066-72
(Sep 2010)
ISSN: 1477-0970 [Electronic] England |
PMID | 20639271
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Immunologic Factors
- Nitrates
- Nitrites
- Nitric Oxide
- Neopterin
- Interferon-beta
- Creatinine
- Interferon beta-1a
|
Topics |
- Adult
- Biomarkers
(urine)
- Chromatography, High Pressure Liquid
- Colorimetry
- Creatinine
(urine)
- Disability Evaluation
- Drug Monitoring
(methods)
- Female
- Humans
- Immunologic Factors
(therapeutic use)
- Interferon beta-1a
- Interferon-beta
(therapeutic use)
- Male
- Middle Aged
- Multiple Sclerosis, Chronic Progressive
(diagnosis, drug therapy, urine)
- Neopterin
(urine)
- Nitrates
(urine)
- Nitric Oxide
(urine)
- Nitrites
(urine)
- Poland
- Predictive Value of Tests
- Time Factors
- Treatment Outcome
- Up-Regulation
|